Formation Bio Doses First Participant in Phase 1 Trial of CNS-Penetrant TYK2 Inhibitor BLKR201
Key Insights
Formation Bio (search) has dosed the first participant in a Phase 1 first-in-human trial of BLKR201 (search), a CNS-penetrant allosteric TYK2 (search) inhibitor, just five months after in-licensing the asset from Lynk Pharmaceuticals (search).
The BLKR201 (search)-101-HV study is a single ascending dose and multiple ascending dose trial in healthy volunteers, with a data readout expected in early 2027.
BLKR201 (search) is designed to regulate immune signaling within the central nervous system and may open therapeutic opportunities across a range of autoimmune and inflammatory conditions.
Formation Bio (search), an AI-native pharma company, today announced dosing of the first participant in a Phase 1, first-in-human clinical trial of BLKR201 (search), an investigational CNS-penetrant allosteric TYK2 (search) inhibitor. The milestone comes just five months after the company in-licensed the asset from Lynk Pharmaceuticals (search) in December 2025, underscoring what Formation Bio describes as the speed enabled by its AI-native development model.
The study, designated BLKR201 (search)-101-HV, is a single ascending dose (SAD) and multiple ascending dose (MAD) trial being conducted in healthy volunteers. A data readout is expected in early 2027. BLKR201 has not been approved by the FDA, and this trial marks the first time the molecule has been evaluated in humans.
Rapid Advancement from Deal Close to Clinical Dosing
"BLKR201 (search) is an example of how Formation Bio (search)'s AI-native development model can expand what is possible for promising medicines," said Benjamine Liu, CEO and Co-Founder of Formation Bio. "By combining deep domain expertise with AI tools purpose built for accelerating drug development — across indication strategy, evidence generation, and trial execution — we were able to rapidly evaluate BLKR201's biology, identify novel development opportunities and indications where its CNS-penetrant and selective TYK2 (search) profile could be most meaningful, and move from deal close to first participant dosed in five months."
Michael Dunn, General Manager of Bleecker Bio (search), the Formation Bio (search) subsidiary developing the asset, noted: "Through our hub-and-spoke model, every asset benefits both from the power of our core in-house development expertise as well as the dedicated attention of a focused team, plugged into Formation Bio's AI ecosystem at every point of development. That combination is what makes this kind of swift development progress possible."
Scientific Rationale and Therapeutic Potential
BLKR201 (search), originally designated as LNK01006, is a next-generation, CNS-penetrant allosteric TYK2 (search) inhibitor designed to regulate immune signaling within the central nervous system. TYK2 is a validated target with an established clinical safety profile, but the CNS exposure and high target selectivity of BLKR201 may open up indications where central or compartmentalized immune pathways are believed to drive disease, including a range of autoimmune and inflammatory conditions.
The compound reflects Lynk Pharmaceuticals (search)' medicinal chemistry expertise, incorporating a highly optimized scaffold engineered for target selectivity, metabolic stability, and CNS penetration. Lynk Pharmaceuticals, founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focuses on the JAK-STAT and TYK2 (search) signaling pathways and has developed multiple Class 1 new drug candidates.
Deal Structure and Partnership
Under the exclusive development and licensing agreement signed in December 2025, Formation Bio (search)'s subsidiary Bleecker Bio (search) obtained rights to LNK01006 (now BLKR201 (search)) outside Greater China. Lynk Pharmaceuticals (search) received a minority equity stake in Bleecker Bio, an upfront payment, and is eligible for additional development, regulatory, and commercial milestones totaling up to $605 million, plus tiered royalties on potential future sales.
Dr. Zhao-Kui (ZK) Wan, Founder, Chairman and Chief Executive Officer of Lynk Pharmaceuticals (search), said: "This milestone marks an important step forward in the global development of BLKR201 (search). This swift progression is an important step in evaluating the clinical potential of our discovery and underscores the power of Formation Bio (search)'s accelerated development model. We look forward to their continued progress as they advance this promising asset, expand the therapeutic opportunities, and address unmet needs across broad patient populations."
Formation Bio (search)'s broader strategy involves partnering, acquiring, or in-licensing drugs from pharma companies and biotechs to develop programs past clinical proof of concept and beyond, leveraging proprietary technology and AI capabilities to bring new medicines to patients more efficiently.